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platelet cytoplasm, 5-HT is transamidated to small GTPases, 
promoting α-granule release and primary hemostasis. Objective — 
We hypothesized that 5-HT could also stimulate platelet receptor 
shedding after binding to the membrane 5-HT receptor (5-HT2AR).
Methods — Western blot and  ow cytometry were used to determine 
levels of the adhesion receptor GPIbα on platelets or its shed 
fragment glycocalicin in plasma and serum from wild-type mice, 
Tph1-/- mice lacking peripheral 5-HT, and mice lacking functional 
tumor necrosis factor-alpha-converting enzyme (TACE, ADAM17). 
Flow chamber experiments and intravital microscopy were used 
to examine adhesive properties of platelets after stimulation of 
5-HT2AR.
Results — Glycocalicin was signi cantly reduced in Tph1-/- plasma 
and serum. In isolated platelets, 5-HT induced signi cant shedding 
of GPIbα, which was increased to 60 % when 5-HT uptake was 
inhibited by the selective serotonin reuptake inhibitor  uoxetine. 
Speci c 5-HT2AR agonism and antagonism suggested activation of 
this receptor. The shedding could not be induced in TACEδZn/δZn 
platelets, suggesting that activated TACE shed GPIbα. Intracellular 
signaling involved phosphorylation of p38 mitogen-activated 
protein kinase rather than G protein signaling. 5-HT2AR stimulation 
decreased platelet adhesion to collagen-bound von Willebrand 
factor under arterial shear (1500/s) and incorporation into FeCl3-
induced thrombi in mesenteric arterioles.
Conclusions — Stimulation of 5-HT2AR on platelets induces TACE-
mediated shedding of GPIbα, the key adhesion molecule under high 
shear conditions. Our observations provide a new pathway through 
which 5-HT could modulate cardiovascular disease.
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Objectif — L’utilisation des inhibiteurs de la cyclooxygenase-2 (COX-
2) est associée à une augmentation des risques cardiovasculaires. 
Nous avons montré dans un modèle d’in ammation, une réduction 
du tonus des artères mammaires humaines à la noradrénaline 
lors de l’induction de la COX-2 (Foudi et al., 2009). Cet effet est 
associé à une forte production des prostaglandines (PG) E2 et I2. Le 
but de notre étude actuelle est d’évaluer, dans ce même modèle 
d’in ammation vasculaire, le rôle de chacune de ces PG et des 
récepteurs qu’elles peuvent activer (EP1-4, IP).
Méthodes — Les artères mammaires humaines ont été obtenues 
des services de cardiologie, de l’hôpital X. Bichat (Paris). Des 
segments d’artère ont été incubés pendant 24 heures dans des 
conditions in ammatoires (interleukine 1β + lipopolysaccharides) 
ou contrôles. Ils sont ensuite placés dans des bains d’organes pour 
mesurer leurs contractions et relaxations. Ainsi des variations 
du tonus vasculaire ont été induites par la noradrénaline ou des 
agonistes aux récepteurs des prostanoïdes en présence ou absence 
d’antagonistes sélectifs. Par ailleurs, l’expression protéique des 
PGI et PGE synthétases et des récepteurs aux prostanoïdes a été 
mesurée par immunohistochimie dans ces préparations.
Résultats — Les contractions induites par la noradrénaline ont été 
signi cativement augmentées (55 %) en présence d’un antagoniste 
au récepteur à la prostaglandine I2 (CAY10441) lorsque les artères 
étaient soumises à des conditions in ammatoires. Par contre, aucun 
effet n’a été observé avec des antagonistes des récepteurs EP2 et 
EP4 de la PGE2. La réactivité vasculaire, contraction ou relaxation 
aux différents prostanoïdes et analogues (mis à part iloprost) 
n’était pas modi ée quelque soit les conditions d’incubation. En n, 
l’immunohistochimie montre que les récepteurs et les enzymes de 
synthèse des PGE2 et PGI2 restent inchangés.
Conclusion — Dans les conditions in ammatoires, l’antagonisme du 
récepteur IP augmente la contraction induite par la noradrénaline 
comme cela a été observé avec les inhibiteurs de la COX-2. Les 
résultats obtenus permettent de conclure que seule la PGI2 est 
responsable de la réduction de la contraction à la noradrénaline 
lorsque la COX-2 est induite.
Foudi et al., Cardiovasc Res. 81,2: 267-277, 2009.
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Sepsis is an archetypal condition with molecular links between 
in ammation and coagulation. Both events can be orchestrated by 
the interaction between circulating and vascular cells that under 
activation release microparticles. Recently, we reported that 
increased circulating microparticles in septic patients play a pivotal 
role in ex vivo vascular function suggesting that they are protective 
against vascular hyporeactivity by maintaining a tonic pressor 
response (Mostefai et al. Am J Resp Crit Care Med 2008). Besides, 
we further demonstrated these effects of septic microparticles in 
human tissue-engineered blood vessel models by comparing the 
contractile response to histamine of two vascular constructs from 
human vascular smooth muscle cells and  broblasts. The  rst model 
is composed of a media solely (TEVM), and the second contained a 
media and an adventitia (TEVMA). Indeed, we showed that septic 
microparticles increased contraction induced by histamine, in 
vascular constructs from TEVM but not in TEVMA. This effect was 
linked to their capacity to decrease vasodilators components, from 
inducible nitric oxide synthase and cyclooxygenase-2 (COX-2), and 
increase mRNA expression of IL-10 in TEVM The present study was 
designed to address the question whether IL-10 is the mediator 
implicated in the protective effect of septic microparticles against 
vascular hyporeactivity observed in sepsis using the two vascular 
constructs, TEVM and TEVMA. For this purpose, the effect of IL-
10 was investigated in the two constructs in presence or absence 
of lipopolysaccharide (LPS). IL-10 treatment did not modify the 
contractile response in both TEVM and TEVMA compared to non-
treated vessels. LPS treatment induced vascular hyporeactivity 
in TEVM but it did not modify the contractile response in TEVMA 
compared to non-treated vessels. Interestingly, IL-10 restores 
contraction in LPS-treated TEVM towards control vessels. The 
mechanisms by which IL-10 enhanced the response are under 
investigation in relation with the COX vasoconstrictor metabolite, 
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thromboxane A2, as reported in our previous manuscript (Mostefai 
et al. 2008). These data demonstrate that IL-10 restores the 
vascular hyporeactivity induced by LPS in tissue-engineered blood 
vessel models.
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Human secreted phospholipases A2 (sPLA2s) represent novel 
attractive therapeutic targets and biomarkers in coronary artery 
diseases (CAD). We have shown that human Group X sPLA2 (hGX 
sPLA2) is present in atherosclerotic lesions and that hGX sPLA2 
modi ed LDL induces foam cell formation. To elucidate whether 
hGX sPLA2 has a causative role in CAD we have screened the human 
PLA2G10 gene to identify frequent polymorphisms, and we have 
examined their possible association with cardiovascular end-points 
and intermediate in ammatory phenotypes in a large prospective 
study of patients with CAD (the AtheroGene study). Although no 
signi cant association was found between the various polymorphisms 
identi ed and lipids or in ammatory markers, patients carriers of the 
C allele of the T-512C polymorphism located in the 5’ untranslated 
region showed a decreased risk of recurrent cardiovascular events. 
Molecular analysis of the only missense variant (R38C) showed its 
functional relevance as it leads to a profound change in expression 
and secretion of hGX sPLA2.
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Objectives — Vascular Cell Adhesion Molecule-1 (VCAM-1) plays 
a major role in the chronic in ammatory processes involved 
in vulnerable atherosclerotic plaque development. It has been 
shown that the technetium-labelled HMC-I derived peptide B2702p 
bound speci cally to VCAM-1 and allowed the ex vivo imaging of 
atherosclerotic lesions in WHHL rabbits. However, B2702p target-
to-background ratio was suboptimal for in vivo imaging of VCAM-1 
expression in atherosclerotic lesions. In order to increase the target 
to background ratio, ten derivatives of B2702p were synthesized 
(B2702p-1 to 10). We hypothesized that technetium radiolabelled 
B2702p derivatives might allow the molecular imaging of VCAM-1 
expression in an experimental model of atherosclerosis.
Material and Methods — A mouse model of focal atherosclerotic 
plaque development induced by left carotid artery ligation in ApoE-
/- mice was used. 99mTc-B2702p (n=9) and 99mTc- B2702p-1 — 10 
(n=3 for each except B2702p-1, n=5, and B2702p-4, n=5) were 
injected intravenously to the anesthetized animals 3 weeks following 
the ligation. Whole-body planar image acquisition was performed 
for 3 hrs with all radiolabelled peptides and SPECT imaging of 6 
additionnal mice was also performed with 99mTc-B2702p-1. The 
animals were then euthanized and the biodistribution evaluated 
by gamma-well counting of excised organs. The expression of 
VCAM-1 in the ligated and contralateral arteries was evaluated by 
immunohistology.
Results — A robust VCAM-1 immunostaining was observed in ApoE-
/- mice in the atherosclerotic lesions at the level of the left carotid 
whereas no VCAM-1 expression was detected in the contralateral 
carotid. Among the ten evaluated peptides, 99mTc-B2702p-1 
exhibited the more favourable properties. By gamma-well counting, 
there was a signi cant 2.0-fold increase in 99mTc-B2702p-1 left-to-
right carotid artery activity ratio (2.61±0.61) and a 3.4-fold increase 
in left carotid-to-blood activity ratio (1.41±0.36) in comparison to 
99mTc-B2702p (1.32±0.23 and 0.41±0.09, respectively, P<0.05 for 
both comparisons). Finally, a higher 99mTc-B2702p-1 activity in 
the left than in the right carotid was observed by SPECT imaging 
(33.3±5.8 vs. 25.1±5.3 cpm/mm²/ID, respectively, P<0.05).
Conclusion — Radiolabelled-B2702p-1 is a potentially useful 
radiotracer for the in vivo molecular imaging of VCAM-1 expression 
in atherosclerotic plaques.
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Objectif — La glycoprotéine VI est le récepteur d’activation 
des plaquettes par les collagènes de type I et de type III. Nous 
avons émis l’hypothèse que nous pourrions développer une sonde 
spéci que du collagène basée sur la spéci cité de GPVI et que cette 
sonde permettrait de visualiser la  brose in vivo par une méthode 
non invasive
Méthodes — Un anticorps bloquant la liaison de GPVI au collagène 
a été utilisé pour cribler une banque peptidique permettant 
d’identi er un motif peptidique cyclique. La capacité du peptide 
à mimer la GPVI a été analysée par des études de liaison et de 
compétition en phase solide. La liaison au collagène tissulaire a 
été analysée par histochimie. L’imagerie in vivo a été réalisée par 
injection du peptide-marqué au Tc-99m dans un modèle de  brose 
cicatricielle sur infarctus du myocarde chez le rat, scintigraphie et 
autoradiographie.
Résultats — Le peptide, nommé collagelin, se lie de manière 
spéci que à l’anticorps anti GPVI 9O12.2 et aux collagènes I et III 
in vitro et la liaison est inhibée par GPVI indiquant que le peptide 
mime GPVI. Cependant le collagelin n’inhibe pas l’agrégation 
des plaquettes induite par le collagène. Les études d’histochimie 
